Corvus Pharmaceuticals, Inc. (CRVS)
13.93
-0.46
(-3.20%)
USD |
NASDAQ |
Sep 08, 16:00
13.93
0.00 (0.00%)
Pre-Market: 08:35
Corvus Pharmaceuticals Total Liabilities (Quarterly) : 13.95M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 13.95M |
| March 31, 2026 | 12.52M |
| December 31, 2025 | 9.914M |
| September 30, 2025 | 8.706M |
| June 30, 2025 | 9.233M |
| March 31, 2025 | 10.11M |
| December 31, 2024 | 36.34M |
| September 30, 2024 | 46.41M |
| June 30, 2024 | 13.34M |
| March 31, 2024 | 6.72M |
| December 31, 2023 | 6.869M |
| September 30, 2023 | 7.653M |
| June 30, 2023 | 8.558M |
| March 31, 2023 | 9.33M |
| December 31, 2022 | 12.12M |
| September 30, 2022 | 15.67M |
| June 30, 2022 | 12.16M |
| March 31, 2022 | 11.57M |
| December 31, 2021 | 12.29M |
| September 30, 2021 | 14.18M |
| June 30, 2021 | 12.99M |
| Date | Value |
|---|---|
| March 31, 2021 | 14.85M |
| December 31, 2020 | 13.38M |
| September 30, 2020 | 13.51M |
| June 30, 2020 | 13.34M |
| March 31, 2020 | 13.76M |
| December 31, 2019 | 12.54M |
| September 30, 2019 | 12.06M |
| June 30, 2019 | 13.46M |
| March 31, 2019 | 11.61M |
| December 31, 2018 | 7.896M |
| September 30, 2018 | 8.375M |
| June 30, 2018 | 10.52M |
| March 31, 2018 | 11.46M |
| December 31, 2017 | 9.94M |
| September 30, 2017 | 11.05M |
| June 30, 2017 | 10.70M |
| March 31, 2017 | 8.876M |
| December 31, 2016 | 7.349M |
| September 30, 2016 | 6.853M |
| June 30, 2016 | 4.953M |
| March 31, 2016 | 4.674M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 239.27M |
| Shareholders Equity (Quarterly) | 225.33M |
| Debt to Equity Ratio | 0.0032 |
| Current Ratio | 16.16 |
| Net Debt Paydown Yield | 0.01% |